"Peptidyl-Dipeptidase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D007703
|
| MeSH Number(s) |
D08.811.277.656.350.350.687
|
| Concept/Terms |
Peptidyl-Dipeptidase A- Peptidyl-Dipeptidase A
- Peptidyl Dipeptidase A
- Angiotensin I-Converting Enzyme
- Angiotensin I Converting Enzyme
- Carboxycathepsin
- CD143 Antigens
- Kininase II
- Dipeptidyl Peptidase A
- Antigens, CD143
- Angiotensin Converting Enzyme
- Kininase A
|
Below are MeSH descriptors whose meaning is more general than "Peptidyl-Dipeptidase A".
Below are MeSH descriptors whose meaning is more specific than "Peptidyl-Dipeptidase A".
This graph shows the total number of publications written about "Peptidyl-Dipeptidase A" by people in this website by year, and whether "Peptidyl-Dipeptidase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peptidyl-Dipeptidase A" by people in Profiles.
-
Wallentin L, Lindb?ck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 11 01; 41(41):4037-4046.
-
Isabel S, Gra?a-Miraglia L, Gutierrez JM, Bundalovic-Torma C, Groves HE, Isabel MR, Eshaghi A, Patel SN, Gubbay JB, Poutanen T, Guttman DS, Poutanen SM. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci Rep. 2020 08 20; 10(1):14031.
-
Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoimmun Rev. 2014 Apr-May; 13(4-5):383-7.
-
Amin SR, Pulido JS. Retinal vasculitis, aneurysms, and neovascularization in Blau syndrome. JAMA Ophthalmol. 2013 May; 131(5):677-80.
-
Martinez Cantarin MP, Ertel A, Deloach S, Fortina P, Scott K, Burns TL, Falkner B. Variants in genes involved in functional pathways associated with hypertension in African Americans. Clin Transl Sci. 2010 Dec; 3(6):279-86.
-
Oru? N, Lamb J, Whitcomb DJ, Sass DA. The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC. Turk J Gastroenterol. 2008 Dec; 19(4):250-3.
-
Charbonneau DE, Hanson ED, Ludlow AT, Delmonico MJ, Hurley BF, Roth SM. ACE genotype and the muscle hypertrophic and strength responses to strength training. Med Sci Sports Exerc. 2008 Apr; 40(4):677-83.
-
Fain JN, Nesbit AS, Sudlow FF, Cheema P, Peeples JM, Madan AK, Tichansky DS. Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes. Metabolism. 2007 Nov; 56(11):1583-90.
-
Park DJ, Woog JJ, Pulido JS, Cameron JD. Minocycline for the treatment of ocular and ocular adnexal sarcoidosis. Arch Ophthalmol. 2007 May; 125(5):705-9.
-
Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg. 2007 May; 204(5):996-1005; discussion 1005-6.